A Superdevice for Mental Health
OAK wearable brain stimulation is the result of over 15 years of clinical research and product development, millions of hours of real-world testing, and a groundbreaking collaboration with the design team behind Beats and Nest. Currently in use at the U.S. Department of Veterans Affairs, we expect FDA clearance for the treatment of anxiety by Summer 2026, and are advancing regulatory approvals for depression and insomnia in 2027.
Complexity, Simplified
Our patent-pending, comfortable, low-dose electrical brain stimulation engages center brain structures intregral to mood, sleep and congnition. This allows one device to rapidly address multiple conditions and support lifelong brain health. We've enrolled over 1500 participants in studies demonstrating safety and effectiveness in treating Major Depressive Disorder, chronic insomnia, PTSD, Bipolar Depression, Parkinson’s Disease, and Substance Use Disorder. Used for 20 minutes, once or twice per day, OAK does not use Bluetooth or require a smartphone –– it represents the easiest and most comfortable way to deliver clinically effective brain stimulation.
Proof-of-Concept
A legacy FDA pathway that existed until 2019 allowed us to distribute our Version 1.0 technology via 14,000 prescribers, demonstrating product-market-fit and yeilding real world feedback that informed the development of Version 2.0 –– OAK. Today, approximately 60,000 people use our Version 1.0 device to maintain remission and brain performance. These customers began investing in Fisher Wallace via equity crowdfunding in 2019, collectively funding $11 million in R&D and lean operations. We intend to partner with institutional investors to support our next phase of growth, including scaling OAK across U.S. government, telemedicine, employer, and medical center channels.
Leadership
Kelly Roman
CO-FOUNDER, CEO, DIRECTOR
The son of a US Army veteran, Kelly graduated from Harvard College and has helped pioneer the wearable brain stimulation category since 2009, with a passion for clinical research, product development, regulatory affairs, manufacturing, patient advocacy, and visual storytelling. Prior to co-founding Fisher Wallace Labs, Kelly spent three years adapting Sun Tzu's The Art of War into a graphic novel for HarperCollins Publishers, and continues drawing inspiration from the ancient text today; his favorite line: The principle on which to manage an army is to set up one standard of courage which all must reach.
Chip Fisher
CO-FOUNDER
Chip originally co-founded Fisher Wallace Labs with the late Dr. Martin Wallace. After Dr. Wallace’s passing shortly following the company’s formation, Chip met co-founder Kelly Roman through Harvard’s alumni network, and together they proceeded to build the company. Chip was the company's sole angel investor and proceeded to develop its broad network of researchers, prescribers, and advisors. The son of radio pioneer Avery Fisher, Chip continues his father’s philanthropic tradition and serves on the Board of the Juilliard Artist Program.
Advisors
Maurizio Fava, MD
ADVISOR
Psychiatrist-In-Chief, Department of Psychiatry, Massachusetts General Hospital (MGH) | Director, Division of Clinical Research, Mass General Research Institute | Executive Director, Clinical Trials Network & Institute | Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School
David Shulkin, MD
ADVISOR
Former US Secretary of Veterans Affairs | Former CEO of Beth Israel Medical Center.
Joan Camprodon-Gimenez, MD, PhD, MPH
ADVISOR
Chief, Division of Neuropsychiatry, MGH | Director, Transcranial Magnetic Stimulation (TMS) Clinical Service, MGH | Director, Laboratory for Neuropsychiatry & Neuromodulation, MGH | Associate Professor of Neurology, Harvard Medical School | Associate Professor of Psychiatry, Harvard Medical School